Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aligned Genetics Inc. (238120:KRX), powered by AI.
Aligned Genetics Inc. is currently trading at ₩3,320. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aligned Genetics Inc. on Alpha Lenz.
Aligned Genetics Inc.'s P/E ratio is 16.4.
“Aligned Genetics Inc. trades at a P/E of 16.4 (fair value) with solid ROE of 8.0%.”
Ask for details →Aligned Genetics Inc. is a biotechnology company that specializes in the development and commercialization of gene therapy solutions. The primary function of Aligned Genetics is to research and manufacture innovative therapies aimed at treating and potentially curing genetic disorders. This enterprise is notable within the healthcare sector, specifically impacting areas related to genetic medicine, rare diseases, and personalized healthcare. By leveraging cutting-edge biotechnological advancements, Aligned Genetics focuses on addressing unmet medical needs, thereby playing a critical role in delivering novel therapeutic options to patients worldwide. The company’s work is significant in the context of modern medicine as it contributes to the broader push toward precision medicine, where treatments are tailored to the individual genetic profiles of patients. Aligned Genetics Inc. collaborates with academic institutions, healthcare providers, and industry partners, ensuring a comprehensive approach to its research and development pipeline. Its contributions are vital in enhancing the scientific community’s understanding of genetic pathways and in facilitating new solutions to complex medical challenges.
“Aligned Genetics Inc. trades at a P/E of 16.4 (fair value) with solid ROE of 8.0%.”
Ask for details →Aligned Genetics Inc. (ticker: 238120) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 67 employees. Market cap is $47.7B.
The current price is ₩3,320 with a P/E ratio of 16.4x and P/B of 1.28x.
ROE is 8.01% and operating margin is 15.25%. Annual revenue is $16.0B.